Pharmaceutical company Dr. Reddy's Laboratories Ltd (BSE:500124) ( NSE:DRREDDY) (NYSE:RDY) announced on Monday the availability of Fulvestrant Injection in 250 mg/5 ml (50 mg/ml) persingle-dose syringe in the US market.
The company said the Fulvestrant Injection in 250 mg/5 ml (50 mg/ml) persingle-dose syringe is the therapeutic equivalent generic version of the US Food and Drug Administration (USFDA) approved Faslodex (fulvestrant) Injection in 250 mg/5 ml (50 mg/ml).
For the most recent 12 months ending in June 2020, the Faslodex brand and generic market had US sales of approximately USD407m MA, according to IQVIA Health.
According to the company, the Fulvestrant Injection, 250 mg/5 mL (50 mg/mL) per single-dose syringe is available in a carton containing two 5 ml single-dose prefilled syringes.
Fulvestrant, sold under the brand name Faslodex, is a medication used to treat hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression as well as HR-positive, HER2-negative advanced breast cancer, concluded the company.
Apotex launches Teriparatide Injection in US
Teva Pharmaceuticals secures FDA approval for generic Forteo (teriparatide injection)
Upsher-Smith Laboratories introduces Pitavastatin Tablets
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Sanofi and Teva collaborate on innovative IBD treatment
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling